Scholarlink

Purpose <p>To assess the effects of nanoparticle albumin-bound (nab) paclitaxel during transarterial chemoembolization (TACE) on local tumor control and survival in breast cancer liver metastases (BCLM) patients.</p> Methods <p>A single-center retrospective study was conducted on BCLM patients included 29 patients who received conventional TACE (c-TACE group) and 30 patients who received TACE plus nab-paclitaxel (nab-paclitaxel group) for the treatment of BCLM.</p> Results <p>At the data cutoff, the overall survival (OS) rate was 45.3%, with no significant differences in 6-, 12-, 18-, and 24-month survival between the treatment groups (<i>P</i> = 0.330). Overall, the disease control rate was 93.3% in the nab-paclitaxel group, compared with 62.1% in the c-TACE (<i>P</i> = 0.01), and the objective response rate was 60% and 44.8% respectively (<i>P</i> = 0.365). The complete response was 13.3% in the nab-paclitaxel group, compared with 3.5% in the c-TACE group (<i>P</i> = 0.371), while the progressive disease was 6.7% and 37.9% respectively (<i>P</i> = 0.01).</p> Conclusion <p>Incorporating nab-paclitaxel into the TACE regimen has the potential to enhance tumor response by improving disease control rates and reducing tumor progression in patients with BCLM.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nab-paclitaxel in conventional trans arterial chemoembolization for breast cancer liver metastasis: it is time to add new drugs to TACE

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月21日

查看全文
  • Hamidreza Rouientan,
  • Mohadese Ahmadzade,
  • Marzieh Jamali,
  • Babak Salevatipour,
  • Jafar Golzarian,
  • Shahram Akhlaghpoor

摘要

Purpose

To assess the effects of nanoparticle albumin-bound (nab) paclitaxel during transarterial chemoembolization (TACE) on local tumor control and survival in breast cancer liver metastases (BCLM) patients.

Methods

A single-center retrospective study was conducted on BCLM patients included 29 patients who received conventional TACE (c-TACE group) and 30 patients who received TACE plus nab-paclitaxel (nab-paclitaxel group) for the treatment of BCLM.

Results

At the data cutoff, the overall survival (OS) rate was 45.3%, with no significant differences in 6-, 12-, 18-, and 24-month survival between the treatment groups (P = 0.330). Overall, the disease control rate was 93.3% in the nab-paclitaxel group, compared with 62.1% in the c-TACE (P = 0.01), and the objective response rate was 60% and 44.8% respectively (P = 0.365). The complete response was 13.3% in the nab-paclitaxel group, compared with 3.5% in the c-TACE group (P = 0.371), while the progressive disease was 6.7% and 37.9% respectively (P = 0.01).

Conclusion

Incorporating nab-paclitaxel into the TACE regimen has the potential to enhance tumor response by improving disease control rates and reducing tumor progression in patients with BCLM.

Graphical Abstract